Worldviews on evidence-based nursing · 2026
Efficacy of Digital Mental Health Interventions for Depression and Anxiety in Older Adults: A Systematic Review and Meta-Analysis.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ibrahim Fatma Magdi, Petkov Iliya, Al-Jabri Mohammed Musaed, Hammoud Ahmad, Khasawneh Mohamad Ahmad Saleem, Ahmed Sirwan Khaled, Shahrour Ghada
Аннотация
BACKGROUND: Older adults face growing risks of depression and anxiety, yet stigma, comorbidities, cost, and limited access impede receipt of conventional care. Digital mental health interventions (DMHIs), including immersive virtual reality (VR), exergaming, and mobile apps, may reduce these barriers.
AIM: To evaluate the efficacy of DMHIs in reducing depressive and anxiety symptoms among adults aged ≥ 50 years.
METHODS: We conducted a PRISMA adherent systematic review and meta-analysis of randomized controlled trials. Interventions included immersive VR, exergaming/physical digital platforms, mobile applications, and digital cognitive training. Standardized mean differences (SMDs) were pooled with random effects models; heterogeneity was assessed with I2.
RESULTS: Nineteen RCTs (n = 718; mean ages 50.9-84.7 years) met inclusion criteria. Across studies, DMHIs significantly reduced depressive symptoms (SMD = -0.656, 95% CI = -0.932 to -0.380; p < 0.001) and anxiety symptoms (SMD = -0.559, 95% CI = -0.740 to -0.380; p < 0.0001). Immersive and physically engaging modalities (e.g., VR, exergaming) outperformed app-based approaches. Heterogeneity ranged from moderate to high (I2 ≈ 69.6%-97%).
LINKING EVIDENCE TO ACTION: Offer DMHIs: especially VR or exergaming when access to in-person therapy is limited or as an adjunct to usual care. Provide brief onboarding and, when feasible, caregiver support to boost adherence and confidence with technology. Select or configure age-friendly interfaces (e.g., large fonts, simple navigation) to address common usability barriers. Integrate DMHIs into stepped-care or rehabilitation pathways and monitor outcomes with validated tools (e.g., GDS, STAI). Address equity by supplying devices/connectivity solutions and consider cost-effectiveness and long-term engagement in implementation plans.
TRIAL REGISTRATION: PROSPERO ID: CRD420250655153.
AIM: To evaluate the efficacy of DMHIs in reducing depressive and anxiety symptoms among adults aged ≥ 50 years.
METHODS: We conducted a PRISMA adherent systematic review and meta-analysis of randomized controlled trials. Interventions included immersive VR, exergaming/physical digital platforms, mobile applications, and digital cognitive training. Standardized mean differences (SMDs) were pooled with random effects models; heterogeneity was assessed with I2.
RESULTS: Nineteen RCTs (n = 718; mean ages 50.9-84.7 years) met inclusion criteria. Across studies, DMHIs significantly reduced depressive symptoms (SMD = -0.656, 95% CI = -0.932 to -0.380; p < 0.001) and anxiety symptoms (SMD = -0.559, 95% CI = -0.740 to -0.380; p < 0.0001). Immersive and physically engaging modalities (e.g., VR, exergaming) outperformed app-based approaches. Heterogeneity ranged from moderate to high (I2 ≈ 69.6%-97%).
LINKING EVIDENCE TO ACTION: Offer DMHIs: especially VR or exergaming when access to in-person therapy is limited or as an adjunct to usual care. Provide brief onboarding and, when feasible, caregiver support to boost adherence and confidence with technology. Select or configure age-friendly interfaces (e.g., large fonts, simple navigation) to address common usability barriers. Integrate DMHIs into stepped-care or rehabilitation pathways and monitor outcomes with validated tools (e.g., GDS, STAI). Address equity by supplying devices/connectivity solutions and consider cost-effectiveness and long-term engagement in implementation plans.
TRIAL REGISTRATION: PROSPERO ID: CRD420250655153.